The transgenic and knock out (KO) animals involving Fgf23 have been highly informative in defining novel aspects of mineral metabolism, but are limited by shortened life span, inability of spatial/temporal FGF23 control, and infertility of the global KO. To more finely test the role of systemic and genetic influences in FGF23 production, a mouse was developed that carried a floxed ('f')-Fgf23 allele (exon 2 floxed) which demonstrated in vivo recombination when bred to globalCre transgenic mice (eIIa-cre). Mice homozygous for the recombined allele ('Δ') had undetectable serum intact FGF23, elevated serum phosphate (p<0.05), and increased kidney Cyp27b1 mRNA (p<0.05) similar to global Fgf23-KO mice. To isolate cellular FGF23 responses during phosphate challenge Fgf23 Δ/f mice were mated with early osteoblast type Iα1 collagen 2.3kb promoter-cre mice (Col2.3-cre) and the late osteoblast/early osteocyte Dentin matrix protein-1-cre (Dmp1-cre). Fgf23 Δ/f /Col2.3-cre + and Fgf23 Δ/f /Dmp1-cre + exhibited reduced baseline serum intact FGF23 versus controls. After challenge with high phosphate diet Cre − mice had 2.1-2.5 fold increased serum FGF23 (p<0.01), but Col2.3-cre + mice had no significant increase, and Dmp1-cre + mice had only a 37% increase (p<0.01) despite prevailing hyperphosphatemia in both models. The Fgf23 Δ/f /Col2.3-cre was bred onto the Hyp (murine XLH model) genetic background to test the contribution of osteoblasts and osteocytes to elevated FGF23 and Hyp disease phenotypes. Whereas Hyp mice maintained inappropriately elevated FGF23 considering their marked hypophosphatemia, Hyp/Fgf23 Δ/f /Col2.3-cre + mice had serum FGF23 <4% of Hyp (p<0.01), and this targeted restriction normalized serum phosphorus and ricketic bone disease. In summary, deleting FGF23 within early osteoblasts and osteocytes demonstrated that both cell types 
Introduction
Phosphate is central to basic cellular functions and is essential for proper mineralization of bone, therefore blood phosphate concentrations are maintained within a fairly narrow range. Serum phosphate levels are controlled by a balance of endocrine effects on intestinal uptake from the diet, coupled with renal handling and storage in bone ( 1 ) . Fibroblast growth factor-23 (FGF23) is a key hormone involved in maintaining phosphate balance, primarily through control of renal phosphate reabsorption ( 2 ) . In kidney, FGF23 interacts with its coreceptor αKlotho (αKL) and an FGF receptor (FGFR) to activate the MAPK pathway ( 3 , 4 ) . These interactions decrease expression of the renal proximal tubule sodium phosphate cotransporters NPT2a and NPT2c, responsible for renal phosphate reabsorption ( 5 , 6 ) . In parallel, serum 1,25(OH) 2 vitamin D (1,25D) is reduced through FGF23-dependent down regulation of the anabolic 1α-hydroxylase (CYP27b1), and increased catabolic enzyme 24-hydroxylase (CYP24a1) expression ( 5 ) . FGF23 is primarily produced in bone ( 7 ) , and FGF23 mRNA and circulating concentrations are influenced by multiple factors including systemic changes in phosphate ( 8 ), 1,25D ( 9 , 10 ), PTH ( 11 ) , iron handling ( 12 ) , as well as local factors including FGF/FGFR1 signaling ( 13 , 14 ) . Although thought to be primarily produced in osteocytes, which cells in bone are the source(s) of FGF23, as well as the mechanisms directing the ability of bone cells to produce FGF23 downstream of the aforementioned factors remain unclear.
Several heritable and acquired metabolic bone diseases are caused by disturbances in FGF23. In this regard, an increase in circulating bioactive FGF23 is associated with autosomal dominant hypophosphatemic rickets (ADHR) ( 15 ) , autosomal recessive hypophosphatemic rickets type 1-3 (ARHR1: mutations in DMP1; ARHR2: mutations in ENPP1; and ARHR3: mutations in FAM20C (Raine syndrome) ( 16 -19 ) ), X-linked hypophosphatemic rickets (XLH) ( 20 ) , as well as tumor induced osteomalacia (TIO) ( 5 , 20 ) . Although these syndromes have heterogeneous genetic causes, they share a common phenotype of elevated FGF23, leading to hypophosphatemia secondary to renal phosphate wasting with inappropriately low or normal serum 1,25D. The reciprocal disorder to ADHR, familial hyperphosphatemic tumoral calcinosis (hFTC), is caused by loss of function mutations in FGF23 ( 21 , 22 ) , the O-glycosylating enzyme GALNT3 ( 23 ) , and αKL ( 24 ) . The GALNT3 and FGF23 mutations result in destabilized FGF23 protein and thus low circulating intact hormone ( 25 , 26 ) . End organ resistance to serum FGF23 is the likely cause of the severe hyperphosphatemia due to αKL inactivating mutations observed in humans of the molecular mechanisms underlying genetic diseases resulting from alterations in FGF23 bioactivity. These models have proven to phenocopy the majority of the key phenotypes in aforementioned diseases of FGF23 excess and reduction. However, the cellular mechanisms and localization of FGF23 production during changes in serum phosphate and in genetic disorders involving FGF23 are unknown. Additionally, the currently available animal models are characterized by severe endocrine and skeletal manifestations and are therefore limited by shortened life span, inability of spatial and temporal FGF23 control, and infertility of the global Fgf23-KO ( 6 , 27 -30 ) .
To more finely examine FGF23 expression and function in vivo, a mouse harboring a conditional Fgf23 allele (flox-Fgf23) was developed. With osteoblast/osteocyte lineagespecific recombination, conditional-null Fgf23 mice had suppressed circulating intact FGF23 that was resistant to normal responses to phosphate challenge. Further, when bred onto the genetic background of the XLH mouse model Hyp, characterized by an osteoblast differentiation defect and aberrant FGF23 production despite prevailing hypophosphatemia, the recombined Fgf23 allele rescued hallmark endocrine and skeletal disease phenotypes.
These findings support that osteocytes and osteoblasts control baseline circulating FGF23, and that targeting osteoblast/osteocyte FGF23 disrupts normal systemic responses to changes in phosphate handling.
Materials and Methods

Animal studies
Animal studies were approved by and performed according to the Institutional Animal Care and Use Committee (IACUC) for Indiana University, and comply with the NIH guidelines for the use of animals in research. Flox-Fgf23 mice were derived as described immediately below and Hyp mice were purchased as live stock (JAX; Bar Harbor, ME). In Hyp studies, littermates were injected with calcein (10 mg/kg) at 7 days, then alizarin red (20 mg/kg) at 2 days, prior to necropsy and tissue harvest according to standard protocols.
Generation of a conditional Fgf23 allele
Exon 2 of the mouse Fgf23 gene was targeted for Cre-mediated recombination, since deletion of this exon is predicted to result in a truncation of FGF23 protein (Supplemental Figure 1 ). To this end, a 9.4 kb target region of mouse Fgf23 identified from BAC clone RP23:142M1 was subcloned into the pSP72 backbone plasmid. A single LoxP site was inserted downstream of exon 2. The 1.7 kb pGK-gb2 LoxP/FRT-flanking Neomycin cassette (Neo R ) was inserted upstream of exon 2, which contained new BamHI and NcoI restriction sites. Restriction enzyme digests and sequencing confirmed the final targeting vector (depicted in Supplemental Figure 2 ). The targeting vector was separated from the vector backbone with NotI and injected into BA1 ES cells. Positive ES cell clones were identified with G418 selection, and homologous recombination events within the Fgf23 locus (Supplemental Figure 2) were confirmed with PCR and Southern blotting (Supplemental Figure 2) . ES cell DNA were digested with NcoI and probed with a 462 bp 3′-external probe for long arm recombination. DNA digested with BamHI and probed with a 515 bp 5′-internal probe confirmed short arm homologous recombination (Supplemental Figure 2) as designed by InGenious, Inc. (Ronkonkoma, NY).
Conditional deletion of Fgf23 in mice
Chimeric mice were mated to the FLP-Cre transgenic mice (C57BL/6 FLP: stock#005703; JAX, Bar Harbor, ME) to simultaneously assess germline transmission and delete the FRTneomycin resistance (Neo R ) cassette, confirmed through PCR genotyping. The F1-generation heterozygous flox-Fgf23 (Fgf23 f/+ ) mice were either intercrossed to generate homozygous flox (Fgf23 f/f ) mice, or bred to generate Fgf23 f/+ /Cre +/− and Fgf23 Δ/+ (Δ=recombined Fgf23 allele) mice using the eIIa-cre (JAX), the 2.3kb promoter rat type Iα1 collagen-cre (Col2.3-cre) ( 31 ) , and the 8kb-Dentin matrix protein 1 (Dmp1)-cre ( 32 ) 
Rodent diets
Mice were weaned at three weeks of age and maintained until euthanasia at 8 weeks on a standard rodent diet (0.7% phosphate and 1.0% calcium, Harlan-Teklad, Inc.; Madison, WI). To induce FGF23 production littermates were placed on a high phosphate ('HighP') diet containing 1.65% phosphate and 1.0% calcium (Diet #TD 88345; Harlan-Teklad), from 6 weeks of age for 2 weeks. Diets and water were provided ad libitum throughout the experimental time frames.
Serum biochemistries
Blood samples were collected from mice at the time of euthanasia by cardiac puncture, or for interim analyses by facial vein bleed according to approved protocols. Routine serum biochemistries were determined in the Laboratory of the Clinical and Translational Sciences Institute (CTSI) of the Indiana University School of Medicine using an automated COBAS MIRA Plus Chemistry Analyzer (Roche Diagnostics; Indianapolis, IN), or using the Inorganic Phosphorous Reagent kit (Pointe Scientific, Inc.; Brussels, Belgium). Serum 'intact' FGF23, and 'total or C-terminal' FGF23 concentrations were assessed using commercial ELISAs (Kainos Laboratories Int'l; Tokyo, Japan (intact); or Immutopics, Int'l; San Clemente, CA (intact and C-terminal)). Serum intact PTH was measured using commercial ELISA (Immutopics Int'l.).
Micro-computed tomography (μCT)
Femurs were removed post-necropsy and fixed in 4% PFA. Bones were scanned using μCT (Skyscan 1172), at 6 micron resolution, to assess trabecular and cortical bone morphometry. A defined region of interest in the distal femur (~0.5 mm from the growth plate and encompassing 1 mm of slices in the proximal direction) was used to determine trabecular bone volume/total volume (BV/TV). A single cortical bone slice (2 mm proximal to the above region of interest) was analyzed for cortical geometry. The terminology and units used are those recommended by the American Society for Bone and Mineral Research Guidelines for assessment of bone microstructure in rodents using μCT ( 34 ) .
Histomophometric analyses
Following μCT analysis, bones were embedded in methyl methacrylate using standard protocols. Mid-sagittal (4 μm) sections of cancellous bone from the distal femur and transverse (~100 μm) sections of the mid-diaphysis were cut using a microtome (ReichertJung 2050 Supercut; Leica Microsystems, Buffalo Grove, IL) and wire-saw (Histosaw; Delaware Diamond Knives), respectively. The cancellous sections were stained with von Kossa tetrachrome according to established protocols. Diaphysis sections were ground to roughly 40 μm thickness. Periosteal and endocortical dynamic bone parameters were obtained using a semi-automatic analysis system (Bioquant OSTEO; Bioquant Image Analysis Co.) attached to a Nikon microscope. The terminology and units used are those recommended by the Histomorphometry Nomenclature Committee of the American Society for Bone and Mineral Research ( 35 ) .
RNA preparation and quantitative RT-PCR (qPCR)
Kidneys were harvested and homogenized in 1 mL of Trizol reagent (Invitrogen/Life Technologies, Inc.; Grand Island, NY) according to the manufacturer's protocol using a TissueTearor rotor-stator (Biospec Products, Inc.; Bartlesville, OK), then further purified using the RNeasy Kit (Qiagen, Inc.; Germantown, MD). RNA samples were tested with intron-spanning primers specific for Fgf23, and vitamin D 1α-hydroxylase (Cyp27b1) mRNAs; mouse β-actin was used as an internal control. The qPCR primers and probes were purchased as pre-optimized reagents (Applied Biosystems/Life Technologies, Inc.). The TaqMan One-Step RT-PCR kit was used to perform qPCR. PCR conditions for all experiments were: 30 min 48°C, 10 min 95°C, followed by 40 cycles of 15 sec 95°C and 1 min 60°C. The data was collected and analyzed by a 7500 Real Time PCR or StepOne Plus systems (Applied Biosystems/Life Technologies, Inc.). The expression levels of mRNAs were calculated relative to appropriate littermate genotype controls, and the 2 −ΔΔCT method described by Livak was used to analyze the data ( 36 ) .
DNA sequencing
Sequencing of genomic DNA following ella-cre-mediated recombination of the flox-Fgf23 alleles was performed using standard PCR (KOD DNA Polymerase; EMD-Millipore, Inc.) to generate gene fragments followed by Exosap (Affymetrix, Inc.; Santa Clara, CA) preparation of templates. Dideoxysequencing was carried out on the genomic fragments by a commercial vendor (SeqWright Genomic Services; Houston, TX) using the forward or reverse PCR primers.
Statistical analysis
Statistical analysis of the in vivo and in vitro data was performed by one-way ANOVA followed by a Tukey post-hoc test and Student's t-test, respectively. Significance for all tests was set at p<0.05. Data are presented as means ± standard error of the mean (SEM).
Results
Development of a murine model harboring an FGF23 conditional-null allele
To develop an in vivo model carrying conditional-null alleles for Fgf23, mouse exon 2 was targeted for Cre-mediated recombination (LoxP sites in introns 1 and 2; diagrammed in Figure 1A (upper panel)), as deletion of this exon is predicted to cause frame shift mutations after residue 70 and a stop codon after residue 89 in the predicted FGF23 protein (Supplemental Figure 1) . The LoxP-Fgf23 construct (see Methods) was delivered to ES cells, and standard protocols were used to derive mice chimeric for the floxed Fgf23 allele.
As determined by PCR and sequencing of founder line DNA, germline transmission of the flox-Fgf23 allele ('flox' or 'f' allele; Fgf23 f/+ mice; Figure 1A (lower panel)) was confirmed. Following initial Fgf23 f/+ intercrosses, it was determined that the mice carrying homozygous, non-recombined LoxP-Fgf23 alleles (Fgf23 f/f ) were normal for serum phosphate, calcium, alkaline phosphatase, and intact and C-terminal FGF23 concentrations from 5-19 weeks of age when compared to Fgf23 f/+ and WT (Fgf23 +/+ ) littermates (see complete listing of biochemistries: Supplemental Table 1 ).
To test Cre-mediated recombination of the flox-Fgf23 allele, Fgf23 f/+ mice were mated with widely-expressed eIIa-Cre transgenic mice by standard breeding regimen. Using PCR primers that spanned the floxed exon 2 region ( Figure 1A ), a 743 bp PCR product was amplified from genomic DNA of these mice (the 'Δ' allele; Figure 1B ). When sequenced, this product showed the expected deletion of exon 2 with the junction of introns 1 and 3 with a single intervening LoxP site (Supplemental Figure 3) . These results demonstrated that the LoxP sites within introns 1 and 2 flanking Fgf23 exon 2 were correctly targeted and did not alter baseline FGF23 expression and phosphate metabolism.
Testing the functional LoxP-Fgf23 allele in vivo
To determine whether the Δ allele was null for FGF23 expression, the Fgf23 Δ/+ mice were either intercrossed, or Fgf23 f/f mice were bred with Fgf23 Δ/+ /ella-cre + mice. Offspring with fully recombined Fgf23 (Fgf23 Δ/f /ella-cre + ; i.e. genotyped as harboring no remnant intact floxed-Fgf23 alleles following exposure to Cre, approximately 40% of offspring) were much smaller than control littermates ( Figure 1C ). Biochemical analyses revealed that these Fgf23 Δ/f /ella-cre + mice had undetectable serum intact FGF23 (p<0.01; Figure 1D ), which paralleled the lack of measureable serum intact FGF23 in Fgf23 Δ/Δ mice (not shown). Similar to the reported Fgf23-KO mice, the Fgf23 Δ/f /ella-cre + mice were hyperphosphatemic compared to controls (p<0.05; Figure 1D ) ( 28 , 29 ) , and had modestly, but not significantly reduced serum calcium. These mice also had elevated kidney vitamin D 1α-hydroxylase mRNA (Cyp27a1, p<0.05; Figure 1D ), consistent with the loss of FGF23-mediated suppression of this gene. Intercrossed Fgf23 Δ/Δ mice had undetectable serum intact FGF23 and undetectable femur Fgf23 mRNA (Supplemental Figure 4) . Thus, targeted deletion of Fgf23 exon 2 produced a conditional allele null for FGF23 expression.
Bone-specific FGF23 deletion and phosphate challenge
To test the contribution and localization of phosphate-sensitive FGF23 production, Fgf23 Δ/f mice (heterozygous Δ mice were used to potentially reduce the background of FGF23-expressing alleles) were bred to the Type Ia1 collagen 2.3kb promoter-cre transgenic line (Col2.3-cre, known to target early osteoblasts through to osteocytes. At 8 weeks of age, Fgf23 Δ/f /Col2.3-cre + mice maintained on control diet had serum intact FGF23 ~50% of same genotype Fgf23 Δ/f /Col2.3-cre − littermates (p<0.01; Figure 2A ) which corresponded with a 75% reduction in femur Fgf23 mRNA (Figure 2A, inset) . Additional phenotypes emerged when mice were placed on a two-week high phosphate ('HighP') diet at six weeks of age to induce FGF23 production (diet previously reported ( 8 )). After receiving the HighP diet, the Fgf23 Δ/f /Col2.3-cre − mice increased serum intact FGF23 2.1 fold (p<0.01 versus control diet; Figure 2A ). In contrast, the Fgf23 Δ/f /Col2.3-cre + mice only slightly elevated intact FGF23, with serum concentrations significantly reduced compared to Fgf23 Δ/f /Col2.3-cre − mice receiving control or HighP diets (p<0.01; Figure 2A ), consistent with an inability to produce FGF23 in response to changes in serum phosphate.
Next, to target FGF23 in osteocytes, the late osteoblast/osteocyte 8kb-promoter Dentin matrix protein-1-cre (Dmp1-cre) transgenic line was bred onto the flox-Fgf23 background. Similar to the crosses with Col2.3-cre, Fgf23 Δ/f /Dmp1-cre + mice had a 40% reduction of basal intact FGF23 on control diet versus Fgf23 Δ/f /Dmp1-cre − controls (p<0.01; Figure 2B ) and consistent with osteocytes maintaining basal FGF23 expression. Femur Fgf23 mRNA was reduced, but did not reach statistical significance ( Figure 2B, inset) . With the provision of the HighP diet, Fgf23 Δ/f /Dmp1-cre − mice showed a significant increase in intact FGF23 (p<0.01; Figure 2B ) whereas the Fgf23 Δ/f /Dmp1-cre + mice had a positive, but markedly blunted response (37% increased versus Fgf23 Δ/f /Dmp1-cre − mice, p<0.001; Figure 2B ).
Although differences in Cre efficiencies cannot be ruled out at this time, the increase in serum FGF23 following Dmp1-cre exposure and HighP diet was greater than the induction in Fgf23 Δ/f /Col2.3-cre + mice (p<0.01; Figure 2B ).
Coincident with reduced FGF23 during phosphate challenge, the Fgf23 Δ/f /Col2.3-cre + mice had elevated serum phosphate concentrations versus Fgf23 Δ/f /Col2.3-cre − mice (p<0.01; Figure 2C ), and versus same genotype, control diet littermates (p<0.01; Figure 2C ). Serum phosphate was not different between Fgf23 Δ/f /Dmp1-cre − and Fgf23 Δ/f /Dmp1-cre + mice during control diet consumption, but after HighP diet, there was a significant elevation in both genotypes (p<0.05; Figure 2C) , with a further elevation in the Fgf23 Δ/f /Dmp1-cre + mice (p<0.05; Figure 2C ). Serum calcium levels were not different between genotype or dietary challenge ( Figure 2D ), and alkaline phosphatase was slightly reduced in Fgf23 Δ/f / Col2.3-cre + mice receiving HighP diet (p<0.05; Figure 2E ). Serum PTH levels also responded to the HighP diet, as both the Fgf23 Δ/f /Col2.3-cre − and Fgf23 Δ/f /Dmp1-cre − mice showed a significant increase compared to those receiving control diet (p<0.05; Figure 2F ). In contrast, PTH was not significantly increased in the the osteoblast/osteocyte targeted conditional mice. The Fgf23 Δ/f /Col2.3-cre +/− and Fgf23 Δ/f / Dmp1-cre +/− mice were also fed a high phosphate and low calcium diet reported to increase FGF23 ( 37 ); this diet produced similar results as the HighP diet for serum intact FGF23 (Supplemental Figure 5) . Thus, when FGF23 was targeted in both osteoblasts and osteocytes using the Col2.3-cre, there was only a slight increase but when deleted from a more mature cell population with the Dmp1-cre, FGF23 showed a modest increase. These findings support that both osteoblasts and osteocytes contribute to basal and phosphate-sensitive serum FGF23 concentrations.
Rescue of the Hyp phenotype with bone-specific Fgf23 targeting
The metabolic bone disorder XLH is due to loss of function mutations in the Phosphate regulating gene with homology to endopeptidases (PHEX) ( 1 , 38 ) . The murine XLH model Hyp has a large 3′ Phex deletion and reflects the majority of the XLH patient disease phenotypes including elevated FGF23, small size, hypophosphatemia with inappropriately normal 1,25D, and rickets/osteomalacia ( 39 , 40 ) . It was previously demonstrated that when Hyp and global Fgf23-KO mice were crossed, the offspring produced were not grossly and biochemically different from the Fgf23-KO mice ( 28 , 29 ) , as the Hyp/Fgf23-KO mice were small, hyperphosphatemic, had skeletal and ectopic calcifications, and undetectable serum FGF23 ( 28 , 29 (phenotypically normal) mice and were normalized for body size ( Figure 3A) , as well as femur ( Figure 3B ) and tail length ( Figure 3B ). At baseline (4 weeks of age) circulating intact FGF23 in Hyp/Fgf23 Δ/f /Col2.3-cre + mice was ~40% of Fgf23 Δ/+ /Col2.3-cre + (p<0.01) and <4% of Hyp concentrations (p<0.01; Figure 3C ), and did not vary over the time course (up to 8 weeks of age) as assessed by interim bleeds ( Figure 3C ). The Hyp mouse is known to manifest reduced serum phosphate and elevated PTH, which was confirmed ( Figure 3D ). Consistent with reversal of the Hyp disease phenotypes, serum phosphate and PTH in Hyp/ Fgf23 Δ/f /Col2.3-cre + mice was normal versus Hyp mice (p<0.01 and p<0.05, respectively; Figure 3D ) and not different from Fgf23 Δ/+ /Col2.3-cre + mice ( Figure 3D ). Thus, in contrast to complete ablation of Fgf23, reduction of serum FGF23 to below WT baseline levels can rescue Hyp disease phenotypes without the severe manifestations of hyperphosphatemia.
The Hyp skeletal phenotype is characterized by osteomalacia, abnormal growth plate, as well as widened distal metaphyses due to the prevailing hypophosphatemia and inhibited mineralization. As observed by μCT, compared to femurs from Fgf23 Δ/+ /Col2.3-cre + mice, femurs from Hyp/Fgf23 Δ/f /Col2.3-cre + mice displayed almost normal shape, lacking the widened distal metaphysis and growth plate typically observed in Hyp mice ( 1 , 39 ), while also exhibiting higher trabecular bone volume ( Figure 4A) 
Discussion
The use of genetic mouse models that delete or over express critical components of the FGF23 bone-kidney signaling axis have markedly enhanced the understanding of phosphate metabolism. Global Fgf23 knockout mice are phenotypically similar to wild type (WT)
littermates at birth ( 28 -30 ) . These mice then become severely hyperphosphatemic with elevated serum calcium and 1,25D over the next several weeks ( 28 -30 ) . FGF23 interacts with an FGF receptor (FGFR) and αKL in the kidney to elicit a renal phosphaturic response ( 3 , 4 ) . Consistent with FGF23-αKL interactions, homozygous deletion of murine αKl results in an animal exhibiting a phenotype virtually identical to the Fgf23-KO mice, with hyperphosphatemia, elevated 1,25D, and reduced PTH ( 4 ). The primary endocrine difference between Fgf23-null and αKl-null is that the latter have markedly elevated circulating FGF23 ( 4 ), likely as a compensatory response to end-organ resistance of the kidneys to FGF23 signaling, and a positive feedback loop resulting from the prevailing elevated 1,25D and hyperphosphatemia. Indeed, placing αKl-null mice on a low phosphate diet ( 41 ) or mating the Fgf23-KO mouse to the Vdr-KO mouse ( 42 ) normalizes the overwhelming majority of Fgf23 allele could undergo homologous recombination. This Cre line is known to have mosaicism ( 43 , 44 ) , however a substantial portion of the flox-Fgf23/eIIa-cre offspring fully recapitulated the phenotype of the global Fgf23-KO mice. In comparison to the global Fgf23-null mice, while receiving a normal diet the Fgf23 conditional-null mice crossed with the Col2.3-and Dmp1-cre transgenic lines had normal serum phosphate concentrations, PTH, calcium, and alkaline phosphatase. Importantly, intact serum FGF23 concentrations were approximately 50% of the respective Cre-controls. Upon challenge with high phosphate diet, the Cre + mice could not maintain normal phosphate metabolism, and similar to the global Fgf23-KO had elevated serum phosphate with normocalcemia. PTH was similarly elevated in the flox-Fgf23/Col2.3-cre − and flox-Fgf23/Dmp1-cre − mice receiving HighP diet, however this effect was blunted in the flox-Fgf23/Col2.3-cre + and flox-Fgf23/ Dmp1-cre + mice. Whether this response was to due to direct or indirect effects of the inability to fully increase FGF23 in response to high phosphate diet remains to be determined. The localization of the cell populations that increase FGF23 in response to elevated serum phosphate in these models (and patients) are unclear however, as to date no 'stand-alone' phosphate sensing receptor analogous to the calcium-sensing receptor (CASR) has been identified. Herein, it was demonstrated that targeted deletion of FGF23 from both osteoblasts and osteocytes restricted the ability of mice to normalize serum phosphate following challenge with high phosphate diet. Indeed, when comparing floxed-Fgf23 mice that were bred onto the Col2.3-cre or the Dmp1-cre backgrounds, both groups had reduced basal intact FGF23 concentrations. When challenged with high phosphate diet, the Col2.3-cre + mice could not significantly elevate FGF23 above their reduced basal levels, whereas the Dmp1-cre + mice had the ability to partially compensate, and raised FGF23 approximately 35-40% of Dmp1-cre − mice. FGF23 production in osteocytes is critical to disease models such as the Dmp1-KO mouse (modeling ARHR type 1) ( 16 ), the deletion of FGF23 from both early osteoblasts and late osteoblast/osteocytes compromises the ability to respond to phosphate challenge, thus osteoblasts and osteocytes play a significant role in phosphate-mediated FGF23 production. Additionally, the mechanisms responsible for the biological 'set point' for circulating FGF23 and serum phosphate are unknown. It has been shown that normal individuals' serum FGF23 levels vary quite widely but that serum phosphate is maintained within a fairly narrow range ( 20 , 45 , 46 ) . We found that selective FGF23 deletion in osteoblasts or osteocytes similarly reduced baseline concentrations yet did not elicit a global knockout phenotype, therefore multiple cell types may be responsible for maintenance of normal circulating intact FGF23.
Mouse models involving pathways that post-translationally modify FGF23 have also been important for relating patient phenotypes to molecular disease mechanisms. Animals null for the O-glycosylating enzyme GalNAc-T3 (Galnt3) cannot glycosylate FGF23 on threonine (T) 178 within the FGF23 proprotein convertase R 176 HT 178 R 179 /SAE motif, and thus produce FGF23 that is rapidly cleaved by the intracellular protease furin ( 25 ) . These mice produce intact FGF23 at concentrations approximately 50% of WT, similar to our results for the Fgf23 Δ/f /Col2.3-cre and Fgf23 Δ/f /Dmp1-cre mice at baseline. Provision of a high phosphate diet to Galnt3-KO mice results in tumoral calcinosis phenotype ( 47 ) , reflective of some patients with loss of function mutations in GALNT3 ( 23 , 48 , 49 ) . We found that with phosphate challenge both Fgf23/Col2.3-cre and Fgf23/Dmp1-cre conditional-nulls retained the capacity to produce some intact FGF23, at approximately one-half of the basal level of WT mice. With exposure to bone specific Cre expression, these mice were also hyperphosphatemic upon high phosphate dietary challenge. This expression profile is reflective of patients with hfTC GALNT3 and FGF23 missense mutations ( 21 , 22 , 50 ) , where the ability to produce FGF23 at minimal levels and carry out low-level renal phosphate metabolism likely prevents early death, as reported in complete Fgf23-null mice ( 28 , 29 ) or a severe hfTC phenotype as reported in a family with an FGF23 deletion and missense mutation ( 51 ) . Serum FGF23 was detectable after targeting recombination to osteoblasts and osteocytes, therefore it is possible that FGF23 is also produced in other cell types within bone such as chondrocytes ( 52 ), or extra-skeletal tissues such as skin and brain ( 53 ) , as well as heart ( 54 ) . Additionally, it cannot be ruled out at this time that some inefficiency of the respective Cre transgenic lines accounts in part for the detectable serum FGF23. The contributions of these other potential sites to circulating FGF23 at baseline and during phosphate diet challenge is currently unknown. Therefore, future studies targeting cells outside of osteoblasts and osteocytes will be important for understanding FGF23 bioactivity under normal circumstances and during disease modeling.
The knockout models involving FGF23 and its co-receptor αKL have been used in breeding strategies to genetically determine the mechanisms underlying diseases of FGF23 over production. When the global Fgf23-KO was crossed with the mouse model of XLH, the Hyp mouse, the Fgf23-KO phenotype dominated the Hyp phenotype causing severe hyperphosphatemia. ( 28 , 29 ) . The Hyp mouse has a defect in osteoblast differentiation, producing cortical bone cells with elevated Type 1 collagen, matrix protein disturbances ( 40 ) , as well as increased alkaline phosphatase and FGF23 ( 7 , 55 , 56 ) . Additionally, this model has an intrinsic defect whereby FGF23 is approximately 10-fold elevated in the face of significant hypophosphatemia ( 57 ), typically a potent FGF23 suppressor via negative feedback. We found that when Fgf23 was targeted in the Hyp/Fgf23 Δ/f /Col2.3-cre cross, the mice had relatively normal body size, but markedly elevated bone volume as well as normal femur length and shape, as opposed to the Hyp manifestations of stunted growth and widened metaphyses due to the severe hypophosphatemia ( 39 Novel therapies that involve inhibiting FGF23 activity with neutralizing antibodies are currently in clinical trials for XLH ( 61 , 62 ) , and were previously shown to correct the major manifestations of hypophosphatemic rickets in the Hyp mouse ( 63 ) . The Hyp/Fgf23 Δ/f / Col2.3-Cre cross resulted in significant reductions in circulating FGF23 compared to Hyp and WT mice, and rescued the hypophosphatemia and Hyp skeletal disease phenotypes with almost complete restoration of normal bone length and shape. These findings support that the inhibition of bioactive FGF23 production to at least one-half of control serum concentrations (or <4% of Hyp) can restore almost normal phosphate metabolism associated with uncontrollable FGF23 excess. Converse to loss of function mutations in FGF23, αKL, and GALNT3, FGF23 transgenic mice whether under control of the Type 1 collagen promoter (Col1a1) ( 6 ) or β-actin ( 27 ) , have severe hypophosphatemia with little to no change in serum calcium, low 1,25D levels and reduced bone mineral density (BMD) ( 6 , 27 ) . A murine model of the ADHR syndrome carrying an R176Q-Fgf23 point mutation can be induced to express elevated FGF23 and an ADHR phenotype during iron deficiency anemia ( 12 , 64 ) . Additionally, although genetically distinct, global or bone-specific conditional knockout of Dmp1 (human DMP1 mutations cause autosomal recessive hypophosphatemic rickets (ARHR) Type 1) ( 16 ) , and the kinase Family with sequence similarity 20, member C (FAM20C; mutations cause ARHR Type 3 or 'Raine syndrome') ( 65 ) result in animals that over express FGF23 and manifest a hypophosphatemic rickets phenotype similar to Hyp mice. Consistent with its proposed role as a key mediator of renal phosphate handling, mice with a common denominator of high circulating FGF23 reproduce the majority of the biochemical and skeletal defects of patients with ADHR, ARHR, XLH and TIO. Thus, our results support the idea that control of FGF23 bioactivity through a targeted, conditional approach could also be useful for dissecting heterogeneous disease mechanisms as well as for testing specific therapeutic approaches in diverse models of FGF23 over production through FGF23 reduction in specific cell populations.
In summary, an animal with a conditional Fgf23 allele was developed, and demonstrated that osteoblasts and osteocytes contribute to the maintenance of normal circulating FGF23 levels. Finally, restricting osteoblasts/osteocytes from inappropriately over-producing FGF23 during prevailing hypophosphatemia can rescue severe Hyp phenotypes.
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